TD Cowen Issues Pessimistic Forecast for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its price objective dropped by research analysts at TD Cowen from $379.00 to $294.00 in a research report issued on Monday,MarketScreener reports. The firm currently has a “hold” rating on the medical instruments supplier’s stock. TD Cowen’s price objective would indicate a potential upside of 102.84% from the company’s previous close.

PODD has been the subject of a number of other reports. Robert W. Baird reduced their price objective on shares of Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Wells Fargo & Company lowered their price target on Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. William Blair assumed coverage on shares of Insulet in a research note on Wednesday, May 20th. They set an “outperform” rating for the company. Oppenheimer lowered their price objective on Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Finally, Evercore dropped their price target on Insulet from $240.00 to $200.00 in a research note on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $252.04.

Insulet Price Performance

PODD stock opened at $144.94 on Monday. The stock has a market cap of $10.04 billion, a PE ratio of 33.71, a price-to-earnings-growth ratio of 1.14 and a beta of 1.13. The stock has a 50-day moving average price of $183.55 and a two-hundred day moving average price of $244.77. Insulet has a 1 year low of $140.63 and a 1 year high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same quarter last year, the firm earned $1.02 EPS. Insulet’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts forecast that Insulet will post 6.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC lifted its stake in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in shares of Insulet during the 4th quarter worth $26,000. Elyxium Wealth LLC purchased a new stake in Insulet during the fourth quarter valued at about $28,000. DV Equities LLC purchased a new position in Insulet in the 4th quarter valued at approximately $28,000. Finally, MV Capital Management Inc. purchased a new stake in Insulet during the 4th quarter worth about $29,000.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.